COVID-19 Pandemic Catalyzes the Transformation of the In-vitro Diagnostics Industry

COVID-19 Pandemic Catalyzes the Transformation of the In-vitro Diagnostics Industry

Future Growth Potential is Enriched by Alternate Testing Sites in the Point-of-Care Testing Segment

RELEASE DATE
11-Dec-2020
REGION
North America
Deliverable Type
Market Research
Research Code: PB69-01-00-00-00
SKU: HC03367-NA-MT_25047
AvailableYesPDF Download

$2,450.00

Special Price $1,837.50 save 25 %

In stock
SKU
HC03367-NA-MT_25047

$2,450.00

$1,837.50save 25 %

DownloadLink
ENQUIRE NOW

Description

This research service provides critical insights into the impact of COVID-19 on the global in-vitro diagnostics (IVD) industry, highlighting the growth opportunities, market revenue, and technology trends that influence its growth. Its three major segments identify the strategic imperatives of the IVD industry, the impact of COVID-19 on the IVD growth environment, and actionable growth and profit opportunities of industry participants. The report highlights the similarities and contrast between the United States, Europe, KSA, and UAE.

Leading IVD players are adopting risk-mitigation measures and reprioritizing their opportunities towards controlling the pandemic. The segment initially grappled with supply chain issues (reagents, swabs) and is expected to follow the trend of active COVID-19 cases. POCT and molecular diagnostics account for 30% of all IVD testing. Major players Roche and Abbott both reported a 29% global sales increase in molecular diagnostics compared to Q1 2019. Government funding will compound these figures. Hospital-based testing unrelated to COVID-19, including immuno-histochemistry, accounts for 57% of the IVD market and was severely impacted by reduced patient volumes.

The report highlights the dynamics of the clinical laboratories and covers the key market growth opportunities that encompass IVD solution requirements, disruptive technologies, and innovative business models. The research includes market trends and future concepts that shed light on revenue forecasts and the importance of certain projects, programs, and partnerships.

Author: Surbhi Gupta

Table of Contents

This research service provides critical insights into the impact of COVID-19 on the global in-vitro diagnostics (IVD) industry, highlighting the growth opportunities, market revenue, and technology trends that influence its growth. Its three major segments identify the strategic imperatives of the IVD industry, the impact of COVID-19 on the IVD growth environment, and actionable growth and profit opportunities of industry participants. The report highlights the similarities and contrast between the United States, Europe, KSA, and UAE. Leading IVD players are adopting risk-mitigation measures and reprioritizing their opportunities towards controlling the pandemic. The segment initially grappled with supply chain issues (reagents, swabs) and is expected to follow the trend of active COVID-19 cases. POCT and molecular diagnostics account for 30% of all IVD testing. Major players Roche and Abbott both reported a 29% global sales increase in molecular diagnostics compared to Q1 2019. Government funding will compound these figures. Hospital-based testing unrelated to COVID-19, including immuno-histochemistry, accounts for 57% of the IVD market and was severely impacted by reduced patient volumes. The report highlights the dynamics of the clinical laboratories and covers the key market growth opportunities that encompass IVD solution requirements, disruptive technologies, and innovative business models. The research includes market trends and future concepts that shed light on revenue forecasts and the importance of certain projects, programs, and partnerships. Author: Surbhi Gupta
More Information
Deliverable Type Market Research
No Index No
Podcast No
Author Surbhi Gupta
Industries Healthcare
WIP Number PB69-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9562-B1,9573-B1,99C6-B1,9627-B1